While expression of PD-L1 in the tumor tissue is currently employed as biomarker for predicting patient response to PD-1 inhibition, it remains controversial and is not part of routine testing in melanoma as significant proportions of patients with PD-L1 negative melanomas have shown treatment response [21–23]. The gene discussed is PDCD1; the disease is melanoma.